Limitations of body mass index to assess body composition due to sarcopenic obesity during leukemia therapy

Leuk Lymphoma. 2018 Jan;59(1):138-145. doi: 10.3109/10428194.2015.1136741. Epub 2016 Jan 27.

Abstract

Obesity as defined by body mass index percentile (BMI%) is strongly associated with relapse and poorer survival in childhood ALL. Whether BMI% accurately reflects body fat percentage (BF%) in this population is unknown. We conducted a prospective study assessing body composition during frontline ALL therapy. Dual-energy X-ray absorptiometry measured BF% and lean muscle mass (LMM) at diagnosis, end of Induction, and end of Delayed Intensification. Sarcopenic obesity (gain in BF% with loss of LMM) was surprisingly common during ALL treatment, resulting in poor correlation between changes in BMI% (expressed as Z-score) and BF% overall (r = -0.05) and within patients (r = -0.09). BMI Z-score and BF% changed in opposite directions in >50% of interval assessments. While BMI% at diagnosis is a suitable predictor of obesity/BF% for epidemiological studies, change in BMI% (as expressed as Z-score) does not reflect body composition. Studies evaluating obesity in leukemia should consider using direct measures of body composition.

Keywords: Adiposity; DXA scan; body fat; body mass index; childhood ALL; obesity.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Absorptiometry, Photon
  • Adiposity
  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Body Composition*
  • Body Mass Index*
  • Child
  • Female
  • Humans
  • Leukemia / complications*
  • Leukemia / therapy
  • Male
  • Obesity / complications*
  • Obesity / diagnosis*
  • Young Adult